HealthQuill Daiichi Sankyo
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population. 
Drugs Health Pharma

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

Read More
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development, automation and software.
Drugs Health Pharma

Daiichi Sankyo sets up robotic lab in US to speed up drug discovery

Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type of lung cancer.
Drugs Medical Pharma

AstraZeneca, Daiichi’s trial drug for lung cancer, gets US regulator’s nod

The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.

Read More
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of breast cancer in the US.
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.

Read More
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Drugs Health Pharma

AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.

Read More
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a form of lung cancer improved patients’ chances of extending survival without the disease progressing.
Drugs Health Pharma

Daiichi Sankyo-Merck’s trial lung cancer drug meets primary goal

Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a.

Read More
https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/
Drugs Health Pharma

Daiichi Sankyo to pay Merck $170 million for cancer test drug rights

Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.

Read More
Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered at a “fair price.”
Drugs Health Pharma

UK watchdog blocks AstraZeneca, Daiichi’s breast cancer drug

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.

Read More